Acetylcholinesterase inhibitory potency of new pyrazoline derivative
Yazarlar (3)
Doç. Dr. Mehtap TUĞRAK SAKARYA
Atatürk Üniversitesi, Türkiye
Atatürk Üniversitesi, Türkiye
Atatürk Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
|
| Makale Alt Türü | ESCI dergilerinde yayınlanan tam makale |
| Dergi Adı | Journal of Research in Pharmacy |
| Dergi ISSN | 2630-6344 Wos Dergi Scopus Dergi |
| Dergi Tarandığı Indeksler | ESCI |
| Makale Dili | Türkçe |
| Basım Tarihi | 07-2020 |
| Cilt No | 24 |
| Sayı | 4 |
| Sayfalar | 464 / 471 |
| DOI Numarası | 10.35333/jrp.2020.194 |
| Özet |
| Alzheimer's disease (AD) has no current cure and its mechanism is not fully known, but treatments for symptoms are available. Acetylcholinesterase (AChE) has been reported to be an applicable therapeutic target in patient with AD. Acetylcholinesterase inhibitors (AChEIs) are commonly used for it. For this purpose, novel series of pyrazoline based compounds [2-(3-(4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-pyrazol-1-yl)benzo[d]thiazole, 1-9] were synthesized and AChE inhibitory potencies were reported here. The results indicated that compound 1 (Ki= 0.13±0.004 μM) possessed the highest AChE inhibitory effect in series, which is two times more potent than the reference compound Tacrin (Ki= 0.26±0.045 μM). So, pyrazoline derivative 1 can be considered as a lead inhibitor in designing new AChE inhibitors. |
| Anahtar Kelimeler |
| Acetylcholinesterase | Alzheimer disease | Benzothiazol | Pyrazoline |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| SCOPUS | 11 |
| Google Scholar | 14 |